

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Dean L. Engelhardt et al.

Serial No. 10/718,391

Filed: November 19, 2003

Title: IN VITRO PROCESSES FOR PRODUCING MULTIPLE  
COPIES OF PRIMER SEQUENCE-FREE SPECIFIC  
NUCLEIC ACID

Group Art Unit: Not Yet Known

Examiner: Not Yet Known

527 Madison Avenue, 9th Floor  
New York, New York 10022  
February 10, 2005



**FILED BY EXPRESS MAIL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
Attn: Mail Stop SEQUENCE

**REQUEST TO CORRECT FILING RECEIPT**

Dear Sirs:

Applicants through their attorney respectfully request that the Filing Receipt mailed August 10, 2004 be corrected in accordance with the revisions noted on the copy of the Filing Receipt, attached herein as Exhibit A.

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.	EV531083499US
Deposit Date	February 10, 2005
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
 Natalie Bogdanos Reg. No. 51,480	 Date

ENZ-52(C2)

Déan L. Engelhardt et al.

Serial No. 10/718,391

Filed: November 19, 2003

Page 2 (Request To Correct Filing Receipt – February 10, 2005)

The corrections to the Filing Receipt as noted on the attached marked-up copy alter the Domestic Priority data as claimed by the applicant to reflect the following correct priority:

This application is a CON of 10/260,031 06/06/2003

which is a CON of 09/302,816 3/3/1998

which is a DIV of 08/182,621 1/13/94, ABN

No fee is believed due in connection with this Request To Correct Filing Receipt. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Request, the undersigned may be contacted by telephone at (212) 583-0100 during business hours.

Respectfully submitted,



Natalie Bogdanos

Registration No. 51,480

Attorney for Applicants


ENZO LIFE SCIENCES, INC.  
f/k/a Enzo Diagnostics, Inc.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue, 9<sup>th</sup> Floor  
New York, New York 10022  
Tel.: (212) 583-0100; Fax.: (212) 583-0150

LC\USPros\Enz52(c2.RequestToCorrectFilingReceipt.021005

**ENZ-52(C2)**




## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/718,391	11/19/2003	1637	385	Enz-52(C2)	23	13	2

Ronald C. Fedus, Esq.  
 Enzo Life Sciences, Inc.  
 c/o Enzo Biochem, Inc.  
 527 Madison Avenue (9th Floor)  
 New York, NY 10022



CONFIRMATION NO. 9721

## FILING RECEIPT



\*OC000000013500215\*

Date Mailed: 08/10/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Dean L. Engelhardt, New York, NY;  
 Jannis G. Stavrianopoulos, Bay Shore, NY;  
 Elazar Rabbani, New York, NY;  
 James J. Donegan, Long Beach, NY;

## Assignment For Published Patent Application

Enzo Diagnostics, Inc., New York, NY;

## Domestic Priority data as claimed by applicant

This application is a CON of 10/260,031 06/03/2003\* 06/06/2003  
 which is a CON of 09/260,031 03/02/1999\* 09/302,816 03/03/1998  
 which is a DIV of 08/182,621 01/13/1994 ABN  
 (\*)Data provided by applicant is not consistent with PTO records.

## Foreign Applications

If Required, Foreign Filing License Granted: 08/09/2004

Projected Publication Date: To Be Determined - pending completion of Corrected Papers

Non-Publication Request: No

Early Publication Request: No

**\*\* SMALL ENTITY \*\*****Title**

In vitro processes for producing multiple copies of primer sequence-free specific nucleic acid

**Preliminary Class**

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).